anaerobic bacteria

Ertapenem sodium (MK-826) 是碳青霉烯，是一种 β-内酰胺抗生素，具有广谱抗菌活性。

Antibacterial compound 2 是一种有效的抗菌剂，对许多人类兽医病原体有效，对多重耐药葡萄球菌、肠球菌和链球菌，以及厌氧菌有抑制作用。

Balofloxacin 是一种具有口服活性的氟喹诺酮类抗生素，可通过干扰 DNA 促旋酶来抑制细菌 DNA 的合成，对革兰氏阴性，革兰氏阳性和厌氧菌具有广谱抗菌活性。它可研究呼吸道，肠道和泌尿道感染。

Secnidazole (PM-185184) 是一种具有口服活性唑类抗生素，半衰期比甲硝唑更长。它有潜力研究细菌性阴道病。

Tinidazole (CP12574) 是一种对厌氧菌和原生动物具有选择性抗菌活性的 5-硝基咪唑，是一种具有口服活性的抗菌剂。

Metronidazole Benzoate (Benzoyl metronidazole) 是甲硝唑和苯甲酸衍生物，具有抗菌，抗寄生虫，抗滴虫等作用，常用于治疗由厌氧菌引起的感染。

Lincomycin hydrochloride (U10149A) 是由林可链霉菌产生的抗生素，对革兰氏阳性球菌和厌氧菌具有活性。

Cefoxitin (Rephoxitin) 是一种广谱的、可口服的第二代头孢霉素类抗生素。Cefoxitin 干扰细菌细胞壁的合成。其活性谱包括革兰氏阴性和革兰氏阳性菌，通常用于腹腔感染、盆腔感染和某些类型的妇科感染等腹部，对厌氧菌具有高效性。

Morinidazole 具有抗菌活性，可用于厌氧菌引起的阑尾炎、盆腔炎等细菌感染研究。

(6R,7S)-Cefminox sodium heptahydrate (Meicelin) 是一种 Cefminox sodium heptahydrate 的异构体。它也是一种具有广谱抗菌活性的 β-内酰胺头孢菌素抗生素。

Vulpinic Acid (Pulvinic acid methyl ester) 是地衣代谢物，可降低人脐静脉内皮细胞 (HUVEC) 中 H2O2诱导的ROS，氧化应激和氧化应激相关损伤，可作用于厌氧菌、葡萄球菌及肠球菌。它对脉粥样硬化的研究具有潜在的价值。

Ticarcillin sodium (Aerugipen hydrate) 主要用于抗革兰氏阴性菌, 也能用于研究嗜麦芽感染。

Cefepime (BMY-28142) 是一种头孢类抗生素，具有抗菌活性，可诱导神经毒性，抑制革兰氏阳性和革兰氏阴性，可用于研究厌氧菌。

Clinafloxacin (CI-960) 是一种高效广谱氟喹诺酮类抗生素，抑制革兰氏阳性、革兰氏阴性和厌氧病原体。它对金黄色葡萄球菌的 DNA 促旋酶和拓扑异构酶 IV 有抑制作用，IC50值分别为 0.92 µg ml 和 1.62 µg ml。

UG-FA 132 是一种具有高效抗菌活性的化合物，能够针对革兰氏阳性和阴性细菌产生作用，包括铜绿假单胞菌和产乳糖酶菌株，并对厌氧菌具有强大的抑制效果。

Cefotetan Sodium, a second-generation cephalosporin, cephamycin antibiotic, is active against a wide range of both aerobic and anaerobic gram-negative and gram-positive bacteria. Cefotetan disrupts the cell wall synthesis by binding to penicillin-binding

Sancycline is a semi-synthetic tetracycline antibiotic that is more active than tetracycline against 339 strains of anaerobic bacteria (MIC90s = 1 and 32 μg/ml, respectively).

E 4441 is a third-generation difluoroquinolone, which has good activity against G(+) aerobic bacteria and anaerobic bacteria in vitro and in vivo.

Luminamicin is active against anaerobic bacteria, especially Clostridium sp.; isolated from actinomycete strain OMR-59.

PD 131628 is a novel fluoroquinolone that is a bioactive form of PD 131112 or CI-990 for use against anaerobic bacteria.

SC 28538是一种5-硝基咪唑衍生物。它已被证明对脆弱芽孢杆菌、产气荚膜梭菌、阴道滴虫、胎儿滴虫、人型疟原虫和淋病奈瑟菌具有活性。在与284株厌氧菌的比较研究中，SC 28538的活性与甲硝唑或奥硝唑相同。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

A-39183A is an active component of the A-39183 antibiotic complex produced by aerobic fermentation of Streptomyces NRRL 12049. It has activity against penicillin-resistant S. aureus 3055 and S. faecalis X66 (MICs = 32 and 32 μg/ml, respectively) and a variety of Gram-positive and Gram-negative anaerobic bacteria (MICs = 16-128 μg/ml) in an agar dilution assay.

A-54556B is a natural acyldepsipeptide (ADEP) antibiotic isolated from the fermentation broth of S. hawaiiensis. Like the closely related ADEP, A-54556A , A-54556B is effective against Gram-positive bacteria, including penicillin-resistant S. aureus. A-54556B is also effective against many strains of anaerobic bacteria.